Physician profile
Stephen Grevious
NPI 1093753972
$630.24
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.03 · 2021: $39.42 · 2022: $188 · 2023: $59.82 · 2024: $137 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $147.07 | 2021-2025 | Doc Band |
| Tris Pharma INC | $94.66 | 2022 | |
| Merck Sharp & Dohme LLC | $60.97 | 2019-2025 | Proquad, Vaxneuvance, Gardasil 9 |
| Corium, LLC | $50.75 | 2022-2023 | Azstarys |
| Pfizer INC. | $47.98 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $44.37 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $37.15 | 2019-2022 | |
| Sanofi Pasteur INC. | $36.26 | 2019-2022 | |
| Glaxosmithkline, LLC. | $35.78 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Seqirus USA INC | $22.97 | 2025 | Flucelvax |
| Hologic Sales and Service, LLC | $20.66 | 2024 | Third Wave |
| Genentech USA, INC. | $16.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.06 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Grevious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.